Jiayang Zhang
Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort.
Journal: Current oncology (Toronto, Ont.)
Published: July 07, 2026
Establishment of a model to predict the recurrence time of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Journal: Translational cancer research
Published: July 18, 2025
Selective growth of (5, 4) single-walled carbon nanotubes.
Journal: Science bulletin
Published: March 14, 2025
Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.
Journal: BMC cancer
Published: October 22, 2024
Pifithrin-μ sensitizes mTOR-activated liver cancer to sorafenib treatment.
Journal: Cell death & disease
Published: May 03, 2024
Application of micro/nanorobot in medicine.
Journal: Frontiers in bioengineering and biotechnology
Published: December 08, 2023
Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: July 02, 2023
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Journal: BMC cancer
Published: March 29, 2023
Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Journal: Frontiers in oncology
Published: October 21, 2022
The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study.
Journal: Annals of translational medicine
Published: October 18, 2022
A m6A methyltransferase-mediated immune signature determines prognosis, immune landscape and immunotherapy efficacy in patients with lung adenocarcinoma.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: July 23, 2022
Last Updated: 09/26/2026